Lupin gets USFDA nod to market generic drug
New Delhi, March 11
Drug firm Lupin on Friday said it has received approval from the US health regulator to market its anti-epilepsy drug Vigabatrin for Oral Solution in the American market.
The company has received approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA), Vigabatrin for Oral Solution USP (500 mg), Lupin said in a statement.
The Mumbai-based drug firm’s product is the generic equivalent of Lundbeck Pharmaceuticals’ Sabril for Oral Solution.
The product will be manufactured at Lupin’s manufacturing facility in Goa, it added.
As per IQVIA MAT December 2021 data, Vigabatrin for Oral Solution USP (500 mg) had estimated annual sales of USD 275 million (around Rs 2,100 crore) in the US.
Unlock Exclusive Insights with The Tribune Premium
Take your experience further with Premium access.
Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits
Already a Member? Sign In Now
